SCHEMBL24153602

SCHEMBL24153602

CCc1sc2ccccc2c1CN1CCN2C(=O)CN(CCc3ccc(F)cc3)C(=O)C2C1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ MCHR1 Q99705 7/20 0.36
▸ KCNH2 Q12809 7/20 0.36
▸ ACHE P22303 1/20 0.35
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ OPRM1 P35372 2/20 0.34
▸ SIGMAR1 Q99720 2/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ ADRA1B P35368 1/20 0.34
▸ HTR1A P08908 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24153600 0.93 MCHR1 (0.37) HSD17B10CYP2D6MCHR1KCNH2ACHE
SCHEMBL24939892 0.93 LMNA (0.38) CYP2D6CHRM1HTR2AHRH1HTR1A
SCHEMBL24153499 0.87 HTR1A (0.39) HTR1A
SCHEMBL24153493 0.86 HDAC6 (0.38) —
SCHEMBL24153472 0.86 HTR1A (0.39) HTR1A
SCHEMBL24153475 0.85 KMT2A (0.38) MEN1KMT2AHTR1A
SCHEMBL24938892 0.85 NPY1R (0.41) ADRA1DADRA1AADRA1BHTR1A
SCHEMBL24939891 0.85 LMNA (0.42) MEN1KMT2AHTR1A
SCHEMBL24153512 0.85 — —
SCHEMBL24153484 0.83 NPY1R (0.37) HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019094-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME HOLOSMEDIC (KR) 2023-01-19 — — US disclosed
WO-2021261969-A1 PREPARATION METHOD FOR NOVEL COMPOUND 홀로스메딕 주식회사 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019094-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 HSD17B10 1791/4885CYP2D6 4448/4885CHRM1 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback